A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Roche

Status and phase: Completed; Phase 1

Conditions: Non-Hodgkin's Lymphoma

Treatments: Drug: Obinutuzumab; Drug: Rituximab; Drug: DCDS0780A

Study type: Interventional

Funder types: Industry

Identifiers

NCT02453087

GO29687

Details and patient eligibility

About

This open-label, multicenter, Phase 1/1b study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of DCDS0780A in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma. In the combination portion of the study, the safety and tolerability of DCDS0780A in combination with rituximab or obinutuzumab will be assessed.

Enrollment: 66 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Life expectancy of at least 12 weeks
• Histologically confirmed B-cell non-Hodgkin's lymphoma that has relapsed after or failed to respond to at least one prior treatment regimen and for which no suitable therapy of curative intent or higher priority exists
• A clinical indication for treatment as determined by the investigator
• Availability of archival or freshly collected tumor tissue before study enrollment
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Fasting (greater than or equal to [>=] 8 hours) glucose less than or equal to (<=) 160 milligrams per deciliter (mg/dL)
• Participants requiring anti-diabetic medications must be on a stable dose and regimen for >=4 weeks
• Adequate hematologic function without growth factor or transfusion support
• For women who are not postmenopausal (>= 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods as specified in protocol
• For men: agreement to remain abstinent or use a condom plus an additional contraceptive method as specified in protocol

Exclusion criteria

• Prior use of any monoclonal antibody or antibody-drug conjugate within 4 weeks before Cycle 1, Day 1
• Treatment with radiotherapy, any chemotherapeutic agent, systemic steroids used as an anti-neoplastic agent, or any other investigational anti-cancer agent within 2 weeks prior to Cycle 1, Day 1
• Completion of autologous stem cell transplant within 100 days prior to Cycle 1, Day 1
• Prior allogeneic stem cell transplant
• Current or history of CNS lymphoma
• Current Grade greater than (>) 1 toxicity (except alopecia and anorexia) from prior therapy
• Current Grade >1 peripheral neuropathy from any cause
• Glycosylated hemoglobin (HbA1c) >=7.5 percent (%)
• History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
• Prior irradiation to lung fields
• Clinically significant pulmonary disease
• Recent major surgery within 4 weeks prior to Cycle 1, Day 1, other than superficial lymph node biopsies for diagnosis
• Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
• Presence of positive test results for hepatitis B (hepatitis B surface antigen [HbsAg] and/or total hepatitis B core antibody [anti-HBc]) or hepatitis C (hepatitis C virus [HCV] antibody)
• Known history of human immunodeficiency virus (HIV) seropositive status
• Women who are pregnant or lactating or intending to become pregnant during the study
• Any abnormal laboratory values as specified in protocol
• Requirement for any excluded medication as specified in protocol
• History of other malignancy that could affect compliance with the protocol or interpretation of results
• Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications, including inadequately controlled diabetes or significant cardiovascular disease
• Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1, Day 1
• Participants in Phase 1b Stage Only: Vaccination with live vaccines within 6 months before Cycle 1, Day 1

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

66 participants in 3 patient groups

DCDS0780A Monotherapy

Experimental group

Description:

Participants will receive escalating doses of DCDS0780A as intravenous infusion as monotherapy on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).

Treatment:

Drug: DCDS0780A

DCDS0780A + Rituximab

Experimental group

Description:

Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with rituximab at a dose of 375 milligrams per square meter (mg/m\^2) of body surface area as intravenous infusion on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).

Treatment:

Drug: Rituximab

Drug: DCDS0780A

DCDS0780A + Obinutuzumab

Experimental group

Description:

Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion on Days 1, 8, and 15 of Cycle 1, and from Cycle 2 onwards on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).

Treatment:

Drug: DCDS0780A

Drug: Obinutuzumab